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Summary
Chemotherapy plus rituximab has been the mainstay of treatment for fol-
licular lymphoma (FL) for two decades but is associated with immunosup-
pression and relapse. In phase 2 studies, lenalidomide combined with
rituximab (R2) has shown clinical synergy in front-line and relapsed/refrac-
tory FL. Here, we show that lenalidomide reactivated dysfunctional T and
Natural Killer (NK) cells ex vivo from FL patients by enhancing prolifera-
tive capacity and T-helper cell type 1 (Th1) cytokine release. In combina-
tion with rituximab, lenalidomide improved antibody-dependent cellular
cytotoxicity in sensitive and chemo-resistant FL cells, via a cereblon-depen-
dent mechanism. While single-agent lenalidomide and rituximab increased
formation of lytic NK cell immunological synapses with primary FL
tumour cells, the combination was superior and correlated with enhanced
cytotoxicity. Immunophenotyping of FL patient samples from a phase 3
trial revealed that R2 treatment increased circulating T- and NK-cell counts,
while R-chemotherapy was associated with reduced cell numbers. Finally,
using an in vitro model of myeloid differentiation, we demonstrated that
lenalidomide caused a reversible arrest in neutrophil maturation that was
distinct from a cytotoxic chemotherapeutic agent, which may help explain
the lower rates of neutropenia observed with R2 versus R-chemotherapy.
Taken together, we believe these data support a paradigm shift in the treat-
ment of FL – moving from combination immunochemotherapy to
chemotherapy-free immunotherapy.
Keywords: lenalidomide, follicular lymphoma, non-Hodgkin lymphoma,
immunomodulation, antibody-dependent cell-mediated cytotoxicity.
Follicular lymphoma (FL) is the most common form of
indolent non-Hodgkin lymphoma (NHL) in the United
States and Europe and accounts for roughly 20% of NHL
cases globally (Perry et al, 2016; Teras et al, 2016). FL pre-
sents a variable clinical course but is ultimately incurable.
Treatment approaches vary, from a watch-and-wait strat-
egy to monotherapy with anti-CD20 antibody to
immunochemotherapy. The latter combines rituximab with
standard chemotherapeutic regimens, such as cyclophos-
phamide, vincristine, and prednisone, with or without dox-
orubicin (CVP or CHOP, respectively) or bendamustine,
with remission rates up to 90% and 5-year overall survival
rates approaching 90% (Rummel et al, 2013; Flinn et al,
2014; Luminari et al, 2016). However, relapse is common
and the median progression-free survival (PFS) after induc-
tion therapy is 6–7 years, with PFS declining after each addi-
tional relapse (Rivas-Delgado et al, 2017; Salles et al, 2017).
Moreover, chemotherapeutic agents have been associated
with immune suppression and impaired lymphocyte recovery
that can persist for up to 2 years after treatment (Saito et al,
2015; Ito et al, 2016; Martin et al, 2017a; Olszewski et al,
2018). Thus, the clinical challenge in FL is to deliver more
tolerable and effective treatment regimens that minimize
immunosuppressive effects and long-term toxicity.
Scientific advances are providing insights into mechanisms
that drive pathogenesis in FL disease. Mutations that can
influence disease progression have been identified in FL cells
(Pastore et al, 2015; Weigert & Weinstock, 2017), and
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cellular and molecular features of the tumour microenviron-
ment have been associated with disease severity and clinical
outcome (Dave et al, 2004; Yang & Ansell, 2012). Natural
killer (NK) and cytotoxic T cells are rendered dysfunctional
through diverse mechanisms, including selective loss of acti-
vating ligands, upregulation of inhibitory checkpoint mole-
cules, and induction of anergy in the absence of
inflammatory cytokines (Yang & Ansell, 2012; Gravelle et al,
2016). In addition, tumour-infiltrating T cells from patients
with FL have been shown to form defective immune synapses
with malignant B cells, which inhibits their ability to recog-
nize and lyse target cells (Ramsay et al, 2009).
Rituximab is an anti-CD20 antibody; its mechanisms of
action are to augment NK cell-mediated killing of malignant B
cells via antibody-dependent cellular cytotoxicity (ADCC), to
enhance antibody-dependent cellular phagocytosis (ADCP)
and to induce complement-mediated killing. However, ritux-
imab activity may be adversely affected by the underlying
immune dysfunction observed in FL patients. For example,
low absolute lymphocyte counts and reduced numbers of cir-
culating NK cells in FL patients prior to treatment are predic-
tive of an inferior response to rituximab (Decaudin et al, 2003;
Shafer et al, 2013). Moreover, combining rituximab with
chemotherapy, such as bendamustine or CHOP, does not miti-
gate the sustained immunosuppression seen in patients with
B-cell lymphoma (Saito et al, 2015; Ito et al, 2016).
Lenalidomide binds to cereblon in the Cullin-4 RING E3
ubiquitin ligase and promotes degradation of the haematopoi-
etic transcription factors IKAROS and AIOLOS (Lopez-Girona
et al, 2012; Chamberlain et al, 2014). In neoplastic B cells,
degradation of these substrates causes apoptosis, whereas in T
cells the result is enhanced co-stimulation signalling and
increased interleukin 2 (IL2) production (Gandhi et al, 2014).
As a single agent, lenalidomide restores the ability of tumour-
infiltrating T cells from patients with B-cell lymphoma to form
functional immune synapses with autologous malignant B cells
(Ramsay et al, 2008, 2009; Hagner et al, 2017). Lenalidomide
in combination with rituximab (R2) has been shown to
enhance activation of healthy donor NK cells and increase
ADCC of various NHL cell lines (Wu et al, 2008; Zhang et al,
2009; Lagrue et al, 2015). In the clinic, R2 has demonstrated
synergy in FL in both front-line and relapsed/refractory set-
tings in phase 2 trials (Fowler et al, 2014; Tuscano et al, 2014;
Leonard et al, 2015; Martin et al, 2017b). Results of the
recently reported phase 3 RELEVANCE trial, evaluating R2 ver-
sus R-chemotherapy in previously untreated advanced FL
patients, demonstrated similar efficacy in the two treatment
arms, but found a greater frequency of grade 3/4 neutropenia
was associated with R-chemotherapy (Morschhauser et al,
2018). R2 immunotherapy has also shown activity in marginal
zone lymphoma (MZL), where the combination achieved an
overall response rate (ORR) of up to 89% in phase 2 studies
(Fowler et al, 2014; Sacchi et al, 2016) and is currently being
evaluated in the phase 3 MAGNIFY study (Andorsky et al,
2018).
Despite demonstrated clinical benefits of R2 in FL and
MZL, the mechanism of action of combination treatment in
the indolent NHL setting has not been well studied. Here,
using primary FL patient samples, we demonstrate that the
combination of lenalidomide and rituximab reactivates dys-
functional NK and T cells, leading to increased cytokine pro-
duction and immune synapse signalling, with enhancement
of NK-mediated ADCC and CD8+ T cell anti-FL activity. We
show that R2 treatment of FL patients enrolled in the RELE-
VANCE trial led to increased circulating T- and NK-cells
compared to R-chemotherapy, which was associated with a
decline in immune cell numbers. Additionally, we investi-
gated treatment-associated neutropenia and provide in vitro
evidence that lenalidomide induced a block in neutrophil
maturation that was reversible and distinct from the cyto-
toxic effects of a chemotherapeutic agent. Taken together,
our laboratory studies and correlative results provide a
mechanistic basis for the R2 synergy observed in the clinic
that supports the rational use of combination chemotherapy-
free immunotherapy for the treatment of FL.
Materials and methods
Patient samples and primary human cells
All patient samples were obtained after written informed con-
sent, in accordance with the Declaration of Helsinki and Inter-
national Council on Harmonization Good Clinical Practice
guidelines, and with approval from the research ethics commit-
tees of all participating institutions. Peripheral blood samples
were collected from patients enrolled in the RELEVANCE study
at screening and at the end of induction therapy with R-CHOP
or R2. For immune synapse bioassays, cryopreserved lymph
node (LN) single-cell suspension samples were obtained from
six treatment-na€ıve patients with FL (clinical grades 1–3A) who
were undergoing diagnostic biopsies. In addition, peripheral
blood samples were obtained from six treatment-na€ıve patients
with leukaemic-phase FL (grade IV; lymphocyte counts
>20 9 109/l). CD4+ and CD8+ T cells were isolated from
patient samples by positive magnetic selection, and malignant B
cells were isolated by negative magnetic selection (to ~95% pur-
ity by flow cytometry), using MagniSort Cell Separation kits
(Thermo Fisher Scientific, Waltham, MA, USA). CD56+ NK
cells were isolated (to ~85% purity by flow cytometry) by mag-
netic selection (MagniSort NK Cell Enrichment Kit) from
peripheral blood mononuclear cells (PBMC) that were har-
vested by density-gradient centrifugation (Histopaque, Sigma-
Aldrich, St Louis, MO, USA).
For other ex vivo experiments, PBMC were isolated from
buffy coats of healthy donors (New York Blood Center, New
York, NY, USA), as previously described (Hagner et al,
2015). Viably-frozen PBMC from na€ıve and relapsed/refrac-
tory FL and MZL patients were purchased from Conver-
santBio (Huntsville, AL, USA), ProteoGenex, (Inglewood,
CA, USA) and BioreclammationIVT (Hicksville, NY, USA).
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Cell lines and cell culture
The FL cell lines, DOHH2 and RL, were obtained from
American Type Culture Collection (ATCC; Manassas, VA,
USA) and Leibniz Institute-DSMZ (Braunschweig, Germany),
respectively. The splenic MZL cell line SLVL was from
RIKEN BioResource Center (Ibaraki, Japan), and the NK-92
cell line was from ATCC. All cell lines were maintained in
RPMI medium [RPMI-1640 with 10% fetal bovine serum
(FBS), supplemented with 2 mmol/L L-glutamine, 1% peni-
cillin/streptomycin and 1 mmol/L sodium pyruvate].
DOHH2 and RL cells were made resistant to bendamustine,
4 hydroperoxycyclophosphamide (4-HC), and doxorubicin
by stepwise exposure to increasing drug concentrations up to
100, 5 and 250 lmol/l, respectively.
Enumeration of T and NK cells in peripheral blood of
patients
Enumeration of CD4 and CD8 T and NK cells in peripheral
blood of patients enrolled in the RELEVANCE trial was per-
formed as previously described (Plonquet et al, 2007).
Briefly, absolute cell counts were derived directly from the
flow cytometry data by using fluorescent beads of calibrated
concentration (‘single platform’ technology). Lymphocytes
were gated according to high-CD45 fluorescence intensity
and low side scatter intensity; CD4 T cells were defined as
CD3+CD4+ lymphocytes, CD8 T cells were defined as
CD3+CD8+ lymphocytes, and NK cells as CD3CD16+ and/
or CD56+ lymphocytes.
See the Data S1 for additional methods.
Results
Lenalidomide demonstrated ex vivo immune stimulatory
effects on T cells and NK cells from FL patient and
healthy donor PBMC
The effect of lenalidomide on CD3-stimulated PBMC from
healthy donors and FL patients, both treatment-na€ıve and
relapsed/refractory, was examined (Fig 1). Lenalidomide
treatment of PBMC from FL patients led to a significant
increase (P < 005) of 16- to 25-fold in surface expression
of CD56, OX40, IL2Ra, and NKp30 on NK cells compared
to dimethyl sulfoxide (DMSO)-treated controls (Fig 1A).
Notably, lenalidomide significantly increased intracellular
granzyme B levels in FL NK cells by 16-fold over DMSO.
Lenalidomide increased expression of CD56 and OX40 17-
and 30-fold in healthy donor NK cells (P < 005) compared
to DMSO. In lenalidomide-treated FL PBMC, CD8+ T cells
showed up to 19-fold higher expression of CD40L, OX40,
HLA-DR, and ICOS (P < 005), while CD40L and ICOS
were significantly increased up to 25-fold by lenalidomide
treatment of healthy donor CD8+ T cells compared to
DMSO (Fig 1B).
Lenalidomide treatment led to 23- to 66-fold increases
in absolute counts of proliferating (CellTracedim) CD4+ T
cells, CD8+ T cells and NK cells in PBMC from FL
patients and 21- to 61-fold increases in these populations
in healthy donor PBMC (P < 005) compared to their
respective DMSO-treated controls (Fig 1C). Lenalidomide
treatment of healthy donor PBMC resulted in a 34-fold
increase in total CD8+ T cell counts but had no effect on
total CD8+ T cell counts in PBMC from FL patients
(Fig 1C). Total CD4+ T and NK cell counts in both FL
and healthy donor PBMC were unaffected by lenalidomide.
Notably, a comparison of absolute cell counts in DMSO-
treated negative controls revealed differences between
PBMC from FL patients and those from healthy donors. In
control FL PBMC, absolute counts of proliferating CD4+ T
cells and CD8+ T cells (012  006 9 109/l and
003  001 9 109/l, respectively) were lower compared
with absolute counts of proliferating CD4+ T cells and
CD8+ T cells (024  005 9 109/l and 011  003 9 109/
l, respectively) in DMSO-treated healthy donor PBMC
(data not shown). This observation is consistent with a
deficit in T cell proliferative capacity in PBMC from FL
patients. Although lenalidomide treatment did not bring
the absolute cell counts in FL PBMC to levels detected in
healthy donor PBMC, the magnitude (fold) of the lenalido-
mide-mediated stimulation, relative to DMSO controls, was
comparable in both sample groups. Thus, lenalidomide was
able to restore proliferative capacity despite the FL immune
deficit.
We next examined the effect of lenalidomide on
ex vivo cytokine release by CD3-stimulated PBMC from
FL patients and healthy donors at 72 h. Lenalidomide sig-
nificantly increased interferon-c (IFN-c), granulocyte-
macrophage colony-stimulating factor (GM-CSF) and
tumour necrosis factor-a (TNF-a) production up to 11-
fold in FL patient cells, relative to DMSO-treated con-
trols. In healthy donor PBMC, IL2, IFN-c, GM-CSF and
TNF-a production were increased up to 13-fold by
lenalidomide (Fig 1D). Absolute levels of released cytoki-
nes were 3 to 5 times lower in DMSO-treated FL PBMC
(IFN-c, 33  18; GM-CSF, 25  17; and TNF-a,
97  52 pg/ml) compared to DMSO-treated healthy
donor PBMC (IFN-c, 98  35; GM-CSF, 75  19; and
TNF-a, 480  29 pg/ml) (data not shown). These data
provide additional evidence that, in the absence of
lenalidomide, immune cells from FL patients had sup-
pressed effector responses upon cross-linking with CD3
compared to healthy donor cells. Taken together, these
results show that ex vivo lenalidomide treatment can aug-
ment the expression of critical co-stimulatory receptors
on T and NK cells, increase their proliferative capacity
and enhance the secretion of T-helper cell type 1 (Th1)
cytokines. Importantly, the immunostimulatory activity of
lenalidomide was able to overcome defective effector
responses in immune cells from FL patients.
Lenalidomide Plus Rituximab Restores Immune Function in FL
ª 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John
Wiley & Sons Ltd. 3
R2 immunotherapy enhanced numbers of circulating T
and NK cells in FL patients in comparison with R-
CHOP therapy
As part of correlative biomarker studies associated with
the RELEVANCE trial (Morschhauser et al, 2018), changes
in T and NK cells in the peripheral blood of 193 FL
patients receiving treatment with either R2 (n = 101) or
R-CHOP (n = 92) were examined. Blood samples were
collected at screening and at the end of induction therapy
(week 24). T cell (CD3/CD4/CD8) and NK cell (CD56/
CD16) populations were enumerated by flow cytometry
(Figs 2 and 3). In patients receiving R-CHOP, median
CD4+ T cell counts declined from baseline to week 24
(from 048 9 109/l to 043 9 109/l, respectively), whereas
CD4+ T cell counts were significantly increased (P < 005)
in the R2 arm (from 051 9 109/l to 079 9 109/l)
(Fig 2A, B). CD8+ T cell counts showed a slight increase
from baseline to week 24 with R2, although the difference
was not significant (Fig 2C). CD8+ T cell counts were
unaltered following R-CHOP (Fig 2C, D). In contrast, NK
cell counts in the R-CHOP group decreased significantly
(P < 005) following therapy (from 018 9 109/l to
012 9 109/l), whereas no significant change was observed
with R2 treatment (Fig 3A, B).
Lenalidomide plus rituximab restored the ability of NK
and T cells from FL patients to form functional immune
synapses with autologous FL B cells
A key mechanism of immune dysfunction identified in
tumour-infiltrating CD4+ or CD8+ T lymphocytes from
lymph node biopsies of FL patients is their inability to mobi-
lize F-actin to the immune synapse with autologous FL B
cells (Ramsay et al, 2009). Here, we investigated formation
of the F-actin lytic NK cell immune synapse using peripheral
blood-derived NK cells and autologous circulating tumour B
cells from patients presenting with leukaemic-phase FL.
Using confocal microscopy with image analysis, we showed
that treatment with rituximab, lenalidomide or their
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Fig 1. Lenalidomide enhances activation of T and NK cells in PBMC from healthy donors and FL patients. CD3-stimulated peripheral blood
mononuclear cells (PBMC) from healthy donors (HD) (n = 3–4) and follicular lymphoma (FL) patients (n = 3–4) were treated with dimethyl
sulfoxide (DMSO) or lenalidomide (1 lmol/l) for 5 days and analysed by flow cytometry. (A-B) Expression of activation markers as mean fluo-
rescent intensity (MFI) on (A) Natural Killer (NK) cells and (B) CD8+ T cells. (C) Total and proliferating [carboxyfluorescein succinimidyl ester
(CFSE)dim] CD4+ T, CD8+ T and CD56+ NK cell counts. (D) Supernatants from stimulated/treated PBMC were collected after 72 h and cytokine
production was analysed by Luminex. All data are normalized to DMSO and presented as mean  standard error of the mean (SEM). *P < 005
by two-way ANOVA.
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combination resulted in significant increases in F-actin poly-
merization (Fig 4A) and increased expression of granzyme B
at NK cell:tumour cell immune synapses (Fig 4B). The com-
bination was superior in enhancing NK cell immunological
synapse formation against FL B cells compared with single
agents (Fig 4A, B). We also asked whether enhanced immune
synapse formation correlated with NK cell killing function.
Cytotoxicity assays revealed that treating FL B cells with
rituximab alone (ADCC) or treating both NK and FL B cells
with lenalidomide induced comparable significant increases
in NK cell-mediated tumour cell killing compared to DMSO
(P < 005). Rituximab-treated cells significantly induced B
cell death by 10% compared to DMSO-treated cells at 4%
(P < 005). Single-agent lenalidomide significantly increased
tumour cell death to 11% (P < 005). However, the combi-
nation demonstrated superior induction of NK lytic killing
activity compared to either drug alone and increased tumour
cell death to 18% (Fig 4C).
Immune synapse formation between lenalidomide treated
CD4+ or CD8+ T cells from lymph node biopsies and autolo-
gous tumour cells showed significantly enhanced F-actin
immune synapse formation with FL tumour cells compared to
DMSO-treated cells (Fig 5A, B), consistent with previous find-
ings (Ramsay et al, 2009). However, treatment of FL tumour
cells with rituximab did not improve the ability of untreated
FL T cells to form immune synapses, and the combination had
no impact on lenalidomide’s effect on F-actin polymerization.
Enhanced immune synapse formation was associated with
increased recruitment of tyrosine-phosphorylated proteins (P-
Tyr) in CD4+ T cells and an increased polarized expression of
granzyme B to CD8+ T cell:FL B cell conjugates (Fig 5A, B
lower images). Cytotoxicity assays demonstrated that lenalido-
mide treatment alone or in combination with rituximab
enhanced cytotoxic T cell activity against primary tumour B
cells compared to rituximab alone or DMSO controls
(Fig 5C).
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Fig 2. Elevation of CD4+ T cell counts in peripheral blood of FL patients receiving R2 compared to R-CHOP. CD4+ T and CD8+ T cells were
enumerated in peripheral blood mononuclear cells (PBMC) from 193 patients with follicular lymphoma (FL) at baseline and after 24 weeks of
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP; n = 92) or rituximab and lenalidomide (R2; n = 101) therapy,
using flow cytometry. (A) Absolute CD4+ T cell counts at baseline and 24 weeks. (B) Percentage change in CD4+ T cell counts from baseline to
week 24 (W24) of R-CHOP or R2 therapy. (C) Absolute CD8+ T cell counts at baseline and 24 weeks. (D) Percentage change in CD8+ T cell
counts from baseline to week 24 of R-CHOP or R2 therapy. Data are presented as median with interquartile range. *P < 005 by one-way ANOVA
(for A and C); *P < 005 by Unpaired t-test (for B and D).
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Lenalidomide in combination with rituximab led to
enhanced ADCC against parental and chemo-resistant
FL cell lines
Previous publications have shown that lenalidomide activates
healthy donor NK cells, leading to greater ADCC against
chronic lymphocytic leukaemia and mantle cell lymphoma
(MCL) cells (Wu et al, 2008; Zhang et al, 2009). We investi-
gated whether treatment of NK cells from FL patients with
lenalidomide would improve ADCC of rituximab-treated or
untreated FL cell lines, DOHH2 and RL (Fig 6). In these
experiments, we also determined whether treatment of FL NK
cells with lenalidomide would potentiate immune-mediated
killing of chemo-resistant DOHH2 and RL cells. Both lenalido-
mide and rituximab as single agents enhanced ADCC, reduc-
ing counts of viable parental DOHH2 cells by 58% and 44%,
respectively, and the combination further enhanced ADCC to
69% compared to DMSO-treated controls (Fig 6A). The
effects of lenalidomide and rituximab as single agents on ben-
damustine-, doxorubicin- or 4-HC-resistant DOHH2 cells
showed significantly enhanced ADCC over DMSO (P < 005),
which was greatest with combination immunotherapy
(Fig 6A–C). The effect of treatment on ADCC was similar
when RL cells were used as target FL cells. Lenalidomide treat-
ment of NK cells from FL patients significantly (P < 005)
enhanced the ADCC of parental RL cells to 31%, while ritux-
imab treatment of the target cells led to 25% decline in viable
RL cells; the combination increased ADCC to 57% significantly
(P < 005) compared to DMSO (Fig 6A). Lenalidomide and
rituximab as single agents significantly induced immune-
mediated cytotoxicity in all chemo-resistant RL cells
(P < 005), and the combination of lenalidomide and ritux-
imab further enhanced ADCC against all resistant RL cells
(Fig 6A–C). Taken together, these data demonstrated compa-
rable ADCC activity against both parental and chemo-resistant
target lymphoma B cells, thus providing supporting evidence
for the clinical activity of lenalidomide plus rituximab in the
setting of chemo-resistant FL.
We tested the functional requirement for cereblon in the
ability of lenalidomide to enhance ADCC against lymphoma
cells. As ADCC is predominantly mediated by NK cells, we
generated NK-92 CRISPR CRBN/ cells lacking cereblon
expression. As expected, lenalidomide treatment of parental
NK-92 cells led to increased ADCC killing of rituximab-trea-
ted DOHH2 cells. However, this activity was significantly
diminished when NK-92 CRISPR CRBN/ cells were used
as effector cells (Fig 6D). These results demonstrate for the
first time that lenalidomide acts directly on NK cells via a
cereblon-dependent mechanism to enhance rituximab-
mediated ADCC.
Lenalidomide is differentiated from chemotherapeutic
agents
Current treatment options for FL encompass a range of
therapeutic regimens, including bendamustine in combina-
tion with obinutuzumab or rituximab (first-line therapy or
second-line and subsequent therapy) (Freedman, 2018).
PBMC from healthy donors were treated with ben-
damustine, ibrutinib or lenalidomide, using drug concen-
trations comparable to doses used in the clinic, and then
co-cultured with rituximab-treated DOHH2 and RL cells
(Figure S1). Treatment of PBMC with bendamustine or
ibrutinib prior to co-culture caused significant reductions
in viability (46% and 41%, respectively) compared to
DMSO-treated controls (Figure S1A). In contrast, lenalido-
mide had no impact on PBMC viability. In co-culture
experiments, lenalidomide in combination with rituximab
significantly enhanced ADCC of DOHH2 and RL cells by
44% and 45%, respectively, compared to DMSO (Fig-
ure S1B, C). In contrast, the combination of rituximab
with bendamustine or ibrutinib did not increase ADCC.
Rather, these combinations showed an inverse dose
response in which ADCC was decreased at the highest
drug concentrations tested. These observations were proba-
bly partly due to the cytotoxic effects of bendamustine and
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patients receiving R-CHOP compared to R2. CD56+ Natural Killer
(NK) cells were enumerated in peripheral blood mononuclear cells
from 188 patients with follicular lymphoma (FL) at baseline and
after 24 weeks of rituximab, cyclophosphamide, doxorubicin, vin-
cristine and prednisone (R-CHOP; n = 90) or rituximab and
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ibrutinib on PBMC. In addition, ibrutinib has been shown
to interfere with in vitro ADCC mediated by therapeutic
anti-CD20 antibodies, that is linked to BTK and ITK inhi-
bition in NK cells (Da Roit et al, 2015; Jerkeman et al,
2017).
The combination of lenalidomide and rituximab showed
enhanced activity in marginal zone lymphoma (MZL)
We evaluated lenalidomide and rituximab in the context of
MZL, using the splenic B cell lymphoma with circulating
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villous lymphocytes (SLVL) cell line as a model. Single agent
lenalidomide and rituximab stimulated PBMC-mediated
ADCC of SLVL cells by up to 18% and 31%, respectively,
while the combination enhanced ADCC by up to 37%
(Figure S2). Thus, lenalidomide, alone or in combination
with rituximab, displayed anti-tumour immunostimulatory
activity in a model of MZL.
Lenalidomide caused a reversible block in neutrophil
maturation, unlike the cytotoxic effects of a
chemotherapeutic agent on neutrophil precursor cells
The effects of lenalidomide and bendamustine were com-
pared on myeloid maturation using clonogenic assays, as
well as an in vitro differentiation assay using bone marrow
(BM) myeloid progenitor (CD34+) cells. Treatment of
myeloid progenitor cells with bendamustine at a range of
drug concentrations, dosed on 2 consecutive days for short
durations (3 h) followed by washout, caused significant
reductions (up to 98%) in granulocyte/macrophage colony-
forming units (CFU-GM) (Fig 7A). In contrast, BM pro-
genitor cells exposed to lenalidomide under the same con-
ditions showed a reduction of only 27% in CFU-GM at
the highest dose. In vitro differentiation of haematopoietic
stem cells was followed by flow cytometry with automatic
gating according to CD33 and CD11b expression to iden-
tify 10 myeloid stages of neutrophil differentiation
(Fig 7B). Mature neutrophils begin developing between
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myeloid stages 7 and 8. To determine the effects on neu-
trophil maturation, CD34+ cells were treated with ben-
damustine or lenalidomide for 14 days, followed by 7 days
with no drug. Exposure to bendamustine caused a signifi-
cant reduction in cell viability, such that cultures were ter-
minated after 7 days of treatment and differentiation could
not be measured. Exposure to lenalidomide blocked
in vitro neutrophil differentiation; however, the block was
reversible, and differentiation was restored after the 7-day
off-drug period (Fig 7C). Taken together, our data showed
that lenalidomide induced a block in neutrophil matura-
tion, which was reversible upon drug washout, while hav-
ing no cytotoxic effect on CFU-GMs or mature
neutrophils. In contrast, bendamustine was cytotoxic
towards neutrophil progenitor cells.
Discussion
R2 has demonstrated clinical activity in FL in both front-line
and relapsed/refractory settings, achieving ORRs of up to
98% and ~77%, respectively (Fowler et al, 2014; Tuscano
et al, 2014; Leonard et al, 2015; Martin et al, 2017b; Morsch-
hauser et al, 2018). However, the molecular mechanisms
underlying R2 clinical synergy in indolent NHL have not
been fully characterized. In this study, we used primary
patient samples to demonstrate that R2 immunotherapy
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enhances immune effector cell functions via complementary
mechanisms of action, summarized in Fig 8.
FL is known to be a disease of immune dysfunction.
Here, we show that lenalidomide single agent reactivates dys-
functional T and NK cells from FL patients, as indicated by
elevated expression of co-stimulatory receptors, enhanced
proliferative capacity, and increased Th1 cytokine release.
These results support recent findings from two clinical stud-
ies. One study noted early T-cell activation in patients with
relapsed FL or DLBCL in response to lenalidomide
monotherapy (Menard et al, 2017), and another revealed
lenalidomide-mediated enhancement of NK cell proliferation
in patients with MCL (Hagner et al, 2017). Results of our
analysis of patient samples from the phase 3 RELEVANCE
trial (Morschhauser et al, 2018) are consistent with those
from a phase 2 trial of R2 in FL, where increased numbers of
memory T cells, NK cells, and other immune cell popula-
tions were detected in peripheral blood of patients, starting
from cycle 2 day 1 of therapy (Fowler et al, 2014; Morsch-
hauser et al, 2018). In contrast, we found that R-CHOP was
associated with declines in both NK and CD4+ T cell counts
in patients in the RELEVANCE study. We also demonstrated
(A)
(C)
(B)
Fig 7. Lenalidomide induces a reversible myeloid maturation arrest while bendamustine induces an irreversible neutrophil cytotoxicity. (A) Bone
marrow CD34+ cells from healthy donors were treated for 3 h exposure with dimethyl sulfoxide (DMSO), lenalidomide or bendamustine on 2
consecutive days, followed by washout. (B) Schematic diagram and representative flow cytometric gating for in vitro differentiation of
haematopoietic stem cells to mature neutrophils. Myeloid stages (1–10) of neutrophil differentiation were automatically gated according to CD33
and CD11b expression. (C) Bone marrow CD34+ cells from healthy donors were cultured with stem cell factor, fms-related tyrosine kinase 3, and
granulocyte colony-stimulating factor to promote in vitro myeloid maturation. Cultures were treated with DMSO (vehicle) or lenalidomide
(20 lM) for 14 days, followed by a 7-day washout. Data represent cells in myeloid stages 1–10 at 0, 5, and 7 days post-drug washout. Cell differ-
entiation and apoptosis were measured by flow cytometry. CFU-GM, granulocyte/macrophage colony-forming unit; CMP, common myeloid pro-
genitor; HSC, haematopoietic stem cell.
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enhancement of immune-mediated cytotoxicity against an
MZL cell line by lenalidomide in combination with ritux-
imab. These preclinical findings provide important insight
for the ongoing phase 3 MAGNIFY trial of R2 in patients
with relapsed/refractory indolent NHL, in which MZL
patients have achieved ORR and confirmed/unconfirmed
complete response (CR/CRu) rates of 66% and 44%, respec-
tively (Coleman et al, 2017).
Using genetically knocked-out cereblon NK cells, we show
for the first time that lenalidomide directly activates NK
cells via a cereblon-dependent mechanism, leading to
enhanced ADCC. Notably, lenalidomide demonstrated
immunostimulatory effects on PBMC from both healthy
donors and FL patients, despite evidence of profound func-
tional defects in immune cells from FL patients. Our autolo-
gous immunological assays revealed that combination
lenalidomide-rituximab enhanced formation of NK cell lytic
immune synapses with target FL cells compared to either
drug alone. In contrast, the restoration of tumour-infiltrat-
ing CD4+ and CD8+ T cell immune synapses with FL
tumour B cells was predominantly mediated by lenalidomide
treatment. Critically, our ex vivo functional data using FL-
derived primary cells demonstrated that the ability of R2
immunotherapy to reactivate NK cell and T cell immune
synapses correlated with increased cytotoxic killing of autol-
ogous FL tumour cells. Notably, the combination was active
against both parental and chemo-resistant lymphoma B cell
lines, suggesting that activation of immune effector cells is a
major contributing mechanism of action for lenalidomide
that is distinct from chemotherapy. These findings support
early results of a phase 3 trial of R2 in relapsed/refractory
FL, in which patients with double-refractory FL have
achieved 1-year PFS rates of 66% and CR/CRu rates of 21%
(Andorsky et al, 2017). Lenalidomide has also demonstrated
immune stimulatory activity in combination with the type II
anti-CD20 antibody obinutuzumab, as recently reported by
Morschhauser et al from their phase 1b (GALEN) study,
where they are assessing the combination in patients with
relapsed/refractory FL (Morschhauser et al, 2018; Vo et al,
2018). Their analysis showed that lenalidomide monotherapy
prior to the first infusion of obinutuzumab resulted in reac-
tivation of peripheral blood T cells (Menard et al, 2017).
Moreover, lenalidomide in combination with obinutuzumab
reversed an immature NK phenotype and induced activation
of circulating NK cells (Vo et al, 2018). These findings are
similar to the effects we observed when NK cells from FL
patients were treated with combination lenalidomide-rituxi-
mab ex vivo.
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Fig 8. Complementary mechanisms of lenalidomide and rituximab induce immune-mediated cytotoxicity in FL tumour cells. Lenalidomide sin-
gle-agent resulted in increased Natural Killer (NK)cell (orange) and T cell (blue) activation and proliferation and enhanced immune synapse for-
mation, leading to apoptosis of follicular lymphoma (FL) cells (grey). Rituximab treatment of target FL cells led to NK cell–mediated antibody-
dependent cellular cytotoxicity (ADCC) of FL cells. Combining lenalidomide with rituximab resulted in enhancement of tumour apoptosis
through complementary mechanisms.
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For FL patients, whose course of disease spans many years,
the goal is to offer safer treatment options with a more tolera-
ble safety profile compared to standard chemotherapy, which
is often associated with immune suppression and lymphope-
nia (Garcia Munoz et al, 2014; Sarkozy et al, 2017; Olszewski
et al, 2018). In addition to the effect lenalidomide has on lym-
phocytes, there are also effects on the myeloid lineage of cells.
Using an in vitro model of myeloid differentiation, we show
that lenalidomide induced a block in neutrophil maturation,
which was reversible by drug wash-out, with no loss of cell
viability. Restoration of bone marrow precursor cell popula-
tions after treatment with a cytotoxic agent would require
considerable time, consistent with clinical observations of
impaired lymphocyte recovery in patients treated with R-
bendamustine or R-CHOP (Garcia Munoz et al, 2014; Ito
et al, 2016). Thus, while neutropenia remains one of the
major toxicities associated with both chemotherapy and
lenalidomide-rituximab, our studies suggest the duration of
neutrophil recovery is likely to be longer in chemotherapy-
treated patients in comparison with lenalidomide-treated
patients. Our preclinical findings are consistent with the safety
analysis from the RELEVANCE study, which reported that a
higher percentage of patients in the R-chemotherapy group
had grade 3 or 4 neutropenia, compared with the R2 group
(50% vs. 32%, respectively) (Morschhauser et al, 2018).
In conclusion, we provide preclinical evidence that lenalido-
mide and rituximab have complementary mechanisms of action
and this unique combination is characterized by immune
enhancement, not immunosuppression, as has been observed with
immunochemotherapy. This work, along with recent phase 3 clin-
ical data, challenges the paradigm of conventional
immunochemotherapy and supports the rationale for combina-
tion chemotherapy-free immunotherapy for FL patients.
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